TetraLogic Pharmaceuticals Corporation(TLOG)- NASDAQ
  • Fri, Jan. 29, 6:49 AM
    | Fri, Jan. 29, 6:49 AM | 5 Comments
  • Fri, Jan. 22, 9:27 AM
    • In a regulatory filing, TetraLogic Pharmaceuticals (NASDAQ:TLOG) discloses that it will cut 19 employees out of its 29-person workforce by next month. It will book a restructuring charge of $2.2M this quarter which may increase later in the year depending on facility-related charges and other write-downs that have yet to be finalized.
    • In connection with the job cuts, Chief Scientific Officer Dr. G. Glenn Begley and Chief Operating Officer Dr. Lesley Russell will be terminated effective April 19.
    • Earlier this month, shares plummeted after birinapant failed to beat placebo in a mid-stage study in myelodysplastic syndromes.
    • Previously: TetraLogic Pharma -69% after birinapant study shows no clinical benefit (Jan. 6)
    | Fri, Jan. 22, 9:27 AM | 1 Comment
  • Fri, Jan. 8, 5:50 PM
    • Illumina (NASDAQ:ILMN) saw a lot of action from analysts this week. Deutsche Bank initiated coverage with a Hold rating and $192 (16% upside) price target. Avondale Partners initiated with a Market Perform rating and $175 (6% upside) price target. Wells Fargo downgraded it to Market Perform from Outperform with a $170 - 180 price target. Cowen and Company reiterated its Outperform rating and raised its price target to $215 (30% upside). Barclays maintained its Equal Weight rating and raised its price target to $170 - 175.
    • TetraLogic Pharmaceuticals (NASDAQ:TLOG) initiated with Buy rating and $5 (1,463% upside) price target by Roth Capital.
    | Fri, Jan. 8, 5:50 PM | 2 Comments
  • Thu, Jan. 7, 12:41 PM
    | Thu, Jan. 7, 12:41 PM | 1 Comment
  • Thu, Jan. 7, 9:15 AM
    | Thu, Jan. 7, 9:15 AM | 20 Comments
  • Wed, Jan. 6, 6:38 PM
    • TetraLogic Pharmaceuticals (NASDAQ:TLOG) -68.8% AH after announcing that its Phase 2 study of birinapant co-administered with azacitidine in first line higher risk patients suffering from myelodysplastic syndromes failed to demonstrate any clinical benefit over a placebo.
    • In a separate study, an interim analysis of a randomized Phase 2 clinical study of SHAPE, TLOG's proprietary topical HDAC inhibitor, eight of 34 patients showed a clinical benefit to treatment as assessed by CAILS, the primary endpoint.
    | Wed, Jan. 6, 6:38 PM | 16 Comments
  • Dec. 31, 2015, 12:40 PM
    | Dec. 31, 2015, 12:40 PM | 4 Comments
  • Dec. 31, 2015, 12:06 PM
    • TetraLogic Pharmaceuticals (TLOG +34.5%) initiated with Buy rating and $5 (170% upside) price target by Roth Capital.
    • Prima BioMed (PBMD +8.1%) initiated with Buy rating and $6 (400% upside) price target by Roth Capital.
    • Chimerix (CMRX +6.2%) downgraded to Neutral from Overweight JP Morgan. Price target lowered to $15 (69% upside) from $51. Barclays maintains Overweight rating but lowers price target to $12 from $64. Piper Jaffray maintains Overweight rating but lowers price target to $10 from $63. FBR downgrades to Market Perform and reduces price target to $14 from $73.
    | Dec. 31, 2015, 12:06 PM
  • Nov. 4, 2015, 6:19 PM
    • TetraLogic (NASDAQ:TLOG): Q3 EPS of -$0.39 beats by $0.03.
    | Nov. 4, 2015, 6:19 PM
  • Jul. 1, 2015, 9:10 AM
    • Thinly traded nano cap TetraLogic Pharmaceuticals (NASDAQ:TLOG) is up 30% premarket on light volume in response to its announcement of preliminary positive results in a small Phase 2a study of birinapant in combination with azacitidine for the treatment of patients with higher risk myelodysplastic syndromes (MDS).
    • Of the nine patients in the trial. three experienced a complete response, one a bone marrow complete response, one a partial response who then underwent a stem cell transplant and one had stable disease. The overall response rate was, therefore, 67% (n=6/9). Three patients discontinued the regimen prior to receiving four cycles of treatment.
    • A more complete interim analysis will be done later this year.
    • Birinapant is an SMAC-mimetic (Second Mitochondria-Derived Activator of Caspases) that binds to proteins called Inhibitor of Apoptosis proteins, or IAPs, that suppress apoptosis (cell death). 
    | Jul. 1, 2015, 9:10 AM | 3 Comments
  • Jun. 30, 2015, 5:36 PM
    | Jun. 30, 2015, 5:36 PM | 14 Comments
  • May 6, 2015, 12:45 PM
    | May 6, 2015, 12:45 PM
  • May 6, 2015, 10:48 AM
    • TetraLogic Pharmaceuticals (TLOG -59%) halts patient enrollment in a Phase 1 ascending dose trial of its lead product candidate, birinapant, in patients with chronic hepatitis B infection due to cranial nerve palsies observed in the first cohort. No additional details are provided.
    • Birinapant is also being investigated for the potential treatment of multiple cancers. It is an SMAC-mimetic that binds to proteins called Inhibitor of Apoptosis proteins, or IAPs, that suppress apoptosis (cell death). SMAC, Second Mitochondrial Activator of Caspases, is a naturally occurring IAP inhibitor. Cancer cells and cells infected with certain viruses (hep B) have apoptosis-escaping characteristics. Inhibiting the mechanisms that enable rogue cells to avoid cell death increases apoptosis and potentially delivers a therapeutic benefit.
    | May 6, 2015, 10:48 AM | 6 Comments
  • May 1, 2015, 12:45 PM
    | May 1, 2015, 12:45 PM
  • May 1, 2015, 9:17 AM
    • TetraLogic Pharmaceuticals (NASDAQ:TLOG) prices a 6.25M-share public offering of common stock at $4 per share. Underwriters over-allotment is an additional 937.5K shares. Closing date is May 6. Net proceeds will be used for general corporate purposes.
    | May 1, 2015, 9:17 AM | 4 Comments
  • May 1, 2015, 9:13 AM
    | May 1, 2015, 9:13 AM
Company Description
TetraLogic Pharmaceuticals Corp. is a clinical-stage biopharmaceutical company, which is focused on discovering and developing novel small molecule therapeutics in oncology and infectious diseases. It has two clinical-stage product candidates in development: Birinapant, and SHAPE. Birinapant is... More
Sector: Healthcare
Industry: Diagnostic Substances
Country: United States